drugset / Trial / NCT01569464

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464

Phase 3 Completed 150 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.

Timeline

Start
2012-03
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rotigotine Unknown 1 mg Other
Comparator Rotigotine Unknown 2 mg Other
Comparator Rotigotine Unknown 3 mg Other